Search
Cefilavancin
go.drugbank.com/drugs/DB05735InvestigationalCefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.
ZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalAs of August, 2020 the candidate is in Phase II clinical trials[A219758]. … The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758].
Pictilisib
go.drugbank.com/drugs/DB11663InvestigationalPictilisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Advanced Solid Tumours, Metastatic Breast Cancer, and Non-Hodgkin's Lymphoma, Solid Cancers, among others.
Vatreptacog alfa
go.drugbank.com/drugs/DB12409InvestigationalVatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors
5-fluoro-2'-deoxycytidine
go.drugbank.com/drugs/DB12957Investigational5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
go.drugbank.com/drugs/DB16029Investigational2-(5-fluoro-pentyl)-2-methyl-malonic-acid is under investigation in clinical trial NCT00696943 (18F ML-10 for Early Detection of Response of Brain Metastases to SRS).
Fonadelpar
go.drugbank.com/drugs/DB16169InvestigationalFonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease).
MaxAdFVIII
go.drugbank.com/drugs/DB17713ExperimentalMaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.